Collegium Pharmaceutical stock
COLLNASDAQCollegium Pharmaceutical, Inc., HealthcareISIN US19459J1043
52Score 52 out of 100, Neutral
Price and trend
52 / 100
Price history
−45% in one yearThe chart shows daily closes over 12 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 23% below it.
Since April 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 61).
The price is 50% below its 52-week high. Largest decline in 12 years: 74% (December 2015 to May 2017).
Chart figures for advanced users
- SMA 50$22.99
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$32.36
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)61
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$21.53
- The lowest closing price of the last twelve months.
- Resistance$49.84
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Collegium Pharmaceutical, Inc. belongs to the Drug Manufacturers (Specialty & Generic) industry (United States) and, with a market value of $770.98M, is number 69 of 78 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $780.57M (up 23.6% year on year) and earnings of $62.87M (down 9.1%).
- For fiscal 2026, analysts expect on average revenue of $831.97M (up 6.6%) and adjusted earnings per share of $7.48 (up 0.3%).
Show more
- MEQIRI Score 52 out of 100 (Neutral): rank 367 of 714 in Healthcare, median 53.
- The P/E is 25.4 (Drug Manufacturers (Specialty & Generic) median 19.3, own median of recent years 19.2).
- Our model puts fair value at $46.44, with the price 47% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings turn into cashFree cash flow above 500% of earnings over the last 12 months.Fundamentals 61
- Growing faster than its industryRevenue up 20.3% a year since 2020, Drug Manufacturers (Specialty & Generic) median 8.7%.Growth 71
- Earnings per share growingUp 20.5% a year since 2020.Growth 71
Weaknesses
- High debtDebt 3.67 times equity (latest quarter), Drug Manufacturers (Specialty & Generic) median 0.49.Stability 29
- Share price fell sharplyDown 43% over the last 12 months.Momentum 31
- Interest barely coveredOperating profit covers interest only 2.1 times.Stability 29
Its standout strengths are valuation and growth, while momentum and stability hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- price far below its 52-week high
- high price swings
What lowers it
- price not overheated over the past year
Valuation
Valuation signal
Possible value trapIn our model the price counts as cheap below $33.17 and expensive above $77.41 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $74.01 (cash-flow model) and $18.87 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 10%. At 11% the fair value would be $41.84, at 9% it would be $52.81.
Possible value trap: looks cheap, but high risk.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (19.3).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 7.7% on the twelve months before. Revenue turned from negative at the start of the period to positive ($780.57M in the latest year).
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 59%, operating 24%, net 8%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 25 Feb 2027in 105 days
- Last reported
- 5 Nov 2026EPS reported $1.96 (expected $1.86)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $7.48+0.2%
- Revenue
- $831.97M−0.1%
- Earnings per share
- $7.16−1.4%
- Revenue
- $847.7M+0.4%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook mixed
Share price after the results: −17.5%NUCYNTA revenue lowered on weaker net pricing, offset by Azstarys raised to $65 million to $75 million; total product revenue now $825 million to $855 million.
“We are also increasing our revenue outlook for Azstarys, now expecting $65 million to $75 million following successful integration and encouraging early performance. We now expect total product revenues in the range of $825 million to $855 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 6 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 2 insiders sold, $305,089 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Collegium Pharmaceutical
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 52
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (Specialty & Generic)
The next larger and next smaller companies by market value
- VetoquinolVETO.PA $1.13B77
- Harrow HealthHROW $1.1B39
- PharmanutraPHN.MI $906.68M62
- Ironwood PharmaceuticalsIRWD $806.23M71
- EvotecEVT.DE $624.43M32
- Alpha TeknovaTKNO $541M43
- EvolusEOLS $491.12M45
- KamadaKMDA $468.95M66
ETFs that hold Collegium Pharmaceutical
Held by 13 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.05% | 0.35% | €1.21B |
| iShares S&P SmallCap 600 UCITS ETFIUS3 | 0.04% | 0.30% | €2.28B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.04% | 0.30% | €185.82M |
Show 5 more
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.03% | 0.30% | €4.22B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.03% | 0.30% | €2.17B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.02% | 0.30% | €944.34M |
| Avantis Global Small Cap Value UCITS ETFAVWS | 0.01% | 0.39% | €1.47B |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.01% | 0.35% | €8.19B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 18 Sep 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.